Evidence map›Paper›PMID 27872080›Full record

ArticleAntimicrobial agents and chemotherapy2017

Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.

George Sakoulas, Warren Rose, Andrew Berti, Joshua Olson, Jason Munguia, Poochit Nonejuie, Eleanna Sakoulas, Michael J Rybak, Joseph Pogliano, Victor Nizet

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Exebacase Is ActiveAntimicrobial agents and chemotherapy · 2021
    Article
  6. Review
  7. Article
  8. Clofazimine Reduces the Survival ofACS infectious diseases · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Bicarbonate Resensitization of Methicillin-ResistantAntimicrobial agents and chemotherapy · 2019
    Article
  14. Biology ofFrontiers in cellular and infection microbiology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

George SakoulasUniversity of California-San Diego School of Medicine, La Jolla, California, USA gsakoulas@ucsd.edu.
Warren RoseUniversity of Wisconsin-Madison School of Pharmacy, Madison, Wisconsin, USA.
Andrew BertiUniversity of Wisconsin-Madison School of Pharmacy, Madison, Wisconsin, USA.
Joshua OlsonUniversity of California-San Diego School of Medicine, La Jolla, California, USA.
Jason MunguiaUniversity of California-San Diego School of Medicine, La Jolla, California, USA.
Poochit NonejuieDepartment of Biological Sciences, University of California-San Diego, La Jolla, California, USA.
Eleanna SakoulasUniversity of California-San Diego School of Medicine, La Jolla, California, USA.
Michael J RybakEugene Appelbaum College of Pharmacy, Wayne State University, Detroit, Michigan, USA.
Joseph PoglianoDepartment of Biological Sciences, University of California-San Diego, La Jolla, California, USA.
Victor NizetUniversity of California-San Diego School of Medicine, La Jolla, California, USA.
University of California, San Diego · USUniversity of Wisconsin–Madison · USEugene Applebaum College of Pharmacy and Health Sciences · USSharp HealthCare Foundation · USUniversity of Montana · US

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Systems Biology Approach to Redefine Susceptibility Testing and Treatment of MDR Pathogens in the Context of Host ImmunityU01AI124316 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALSSON, BERNHARD O · 2016 to 2020
$10.2M
Cathelicidins in Skin ImmunityR01AI052453 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GALLO, RICHARD L, NIZET, VICTOR · 2002 to 2017
$5.3M
Cathelicidin in Skin ImmunityR37AI052453 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Richard L Gallo, Victor Nizet · 2019 to 2026
$4.6M
TRAINING & OUTREACH COREU54HD071600 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BEST, BROOKIE MANNING · 2011 to 2015
$3.6M
NIAID NIH HHS R37 AI052453NIAID NIH HHS U01 AI124316NICHD NIH HHS U54 HD071600NIGMS NIH HHS T32 GM007752
6 · The paper itself

Abstract

We asked whether beta-lactamase inhibitors (BLIs) increased the activity of daptomycin (DAP) against methicillin-resistant Staphylococcus aureus (MRSA), the peptide antibiotic colistin (COL) against the emerging Gram-negative nosocomial pathogen Acinetobacter baumannii, and the human host defense peptide cathelicidin LL37 against either pathogen. DAP and LL37 kill curves were performed with or without BLIs against MRSA, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA (hVISA). COL and LL37 kill curves were performed against A. baumannii Boron-dipyrromethene (BODIPY)-labeled DAP binding to MRSA grown with the BLI tazobactam (TAZ) was assessed microscopically. The combination of COL plus TAZ was studied in a murine model of A. baumannii pneumonia. TAZ alone lacked in vitro activity against MRSA or A. baumannii The addition of TAZ to DAP resulted in a 2- to 5-log

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsAntimicrobial Cationic Peptidesbeta-Lactamase InhibitorsCathelicidinsCell MembraneColistinDaptomycinDrug Resistance, BacterialDrug SynergismDrug Therapy, CombinationHumansMethicillin-Resistant Staphylococcus aureusMice, Inbred BALB CAnti-Bacterial AgentsAntimicrobial Cationic Peptidesbeta-Lactamase InhibitorsCathelicidinsColistinDaptomycinPenicillanic AcidTazobactambeta-lactamase inhibitorcathelicidincolistindaptomycinpeptide antibiotic

Identifiers

PMID27872080
PMCPMC5278754
OpenAlexW2553333875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.